Human NKG2D-ligands: Cell biology strategies to ensure immune recognition

Frontiers in Immunology

Volumn 3, Issue SEP, 2012, Pages

  Fernández Messina, Lola ^a   Reyburn, Hugh T ^a   Valés Gómez, Mar ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Exosomes; Immune evasion; Innate immunity; MICA B; NKG2D receptor; Shedding; ULBP

Indexed keywords

EID: 84874243786     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00299     Document Type: Review

References (103)

1. Aguera-Gonzalez, S., Boutet, P., Reyburn, H. T., and Vales-Gomez, M. (2009). Brief residence at the plasma membrane of the MHC class I-related chain B is due to clathrin-mediated cholesteroldependentendocytosisandshedding. J. Immunol. 182,4800-4808.
2. Aguera-Gonzalez, S., Gross, C. C., Fernandez-Messina, L., Ashiru, O., Esteso, G., Hang, H. C., Reyburn, H. T., Long, E. O., and Vales-Gomez,M. (2011). Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur. J. Immunol. 41, 3667-3676.
3. Allez, M., Tieng, V., Nakazawa, A., Treton, X., Pacault, V., Dulphy, N., Caillat-Zucman, S., Paul, P., Gornet, J. M., Douay, C., Ravet, S., Tamouza, R., Charron, D., Lemann, M., Mayer, L., and Toubert, A. (2007). CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 132,2346-2358.
4. Antoun, A., Jobson, S., Cook, M., O'Callaghan, C. A., Moss, P., and Briggs, D. C. (2010). Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: extensive polymorphisms and evidence of diversity between human populations. Hum. Immunol. 71, 610-620.
5. Ashiru, O., Bennett, N. J., Boyle, L. H., Thomas, M., Trowsdale, J., and Wills, M. R. (2009). NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J. Virol. 83,12345-12354.
6. Ashiru, O., Boutet, P., Fernandez-Messina, L., Aguera-Gonzalez, S., Skepper, J. N., Vales-Gomez, M., and Reyburn, H. T. (2010). Natural killercellcytotoxicityissuppressedby exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 70, 481-489.
7. Bacon, L., Eagle, R. A., Meyer, M., Easom, N., Young, N. T., and Trowsdale, J. (2004). Two humanULBP/RAET1moleculeswith transmembrane regions are ligands for NKG2D. J. Immunol. 173, 1078-1084.
8. Bahram, S., Bresnahan, M., Geraghty, D. E., and Spies, T. (1994). A second lineage of mammalian major histo-compatibility complex class I genes. Proc. Natl. Acad. Sci. U.S.A. 91, 6259-6263.
9. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., and Spies, T. (1999). Activation of NK cells and T cells by NKG2D, a receptorforstress-inducibleMICA.Science 285,727-729.
10. Bennett, N. J., Ashiru, O., Morgan, F. J., Pang, Y., Okecha, G., Eagle, R. A., Trowsdale,J.,Sissons,J. G.,andWills, M. R. (2010). Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus. J. Immunol. 185,1093-1102.
11. Borchers, M. T., Harris, N. L., Wesselkamper, S. C., Zhang, S., Chen, Y., Young,L.,andLau,G.W.(2006).The NKG2D-activatingreceptormediates pulmonaryclearanceofPseudomonas aeruginosa. Infect. Immun. 74, 2578-2586.
12. Boutet, P., Aguera-Gonzalez, S., Atkinson, S., Pennington, C. J., Edwards, D. R., Murphy, G., Reyburn, H. T., and Vales-Gomez, M. (2009). Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J. Immunol. 182, 49-53.
13. Brown, M. G., Fulmek, S., Matsumoto, K., Cho, R., Lyons, P. A., Levy, E. R., Scalzo, A. A., and Yokoyama, W. M. (1997). A 2-Mb YAC contig and physicalmapofthenaturalkillergene complex on mouse chromosome 6. Genomics 42,16-25.
14. Burgess, S. J., Marusina, A. I., Pathmanathan, I., Borrego, F., and Coligan, J. E. (2006). IL-21 downregulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J. Immunol. 176,1490-1497.
15. Butler, J. E., Moore, M. B., Presnell, S. R., Chan, H. W., Chalupny, N. J., and Lutz, C. T. (2009). Proteasome regulation of ULBP1 transcription. J. Immunol. 182,6600-6609.
16. Capraru, D., Muller, A., Csernok, E., Gross, W. L., Holl-Ulrich, K., Northfield, J., Klenerman, P., Herlyn, K., Holle, J., Gottschlich, S., Voswinkel, J., Spies, T., Fagin, U., Jabs, W. J., and Lamprecht, P. (2008). Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. Clin. Immunol. 127, 144-150.
17. Castriconi, R., Cantoni, C., Della Chiesa, M.,Vitale,M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., and Moretta, A. (2003). Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl.Acad. Sci. U.S.A.100, 4120-4125.
18. Cerboni, C., Neri, F., Casartelli, N., Zingoni, A., Cosman, D., Rossi, P., Santoni, A., and Doria, M. (2007). Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptorNKG2Dandinhibitsnaturalkiller cell-mediated cytotoxicity. J. Gen. Virol. 88,242-250.
19. Collins, R. W. (2004). Human MHC class I chain related (MIC) genes: their biological function and relevance to disease and transplantation. Eur. J. Immunogenet. 31, 105-114.
20. Cosman, D., Mullberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., and Chalupny, N. J. (2001). ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123-133.
21. Coudert, J. D., Zimmer, J., Tomasello, E., Cebecauer, M., Colonna, M., Vivier, E., and Held, W. (2005). Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106,1711-1717.
22. Chalupny, N. J., Rein-Weston, A., Dosch, S., and Cosman, D. (2006). Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem. Biophys. Res. Commun. 346,175-181.
23. Chalupny, N. J., Sutherland, C. L., Lawrence, W. A., Rein-Weston, A., and Cosman, D. (2003). ULBP4 is a novel ligand for human NKG2D. Biochem.Biophys.Res.Commun.305, 129-135.
24. Champsaur, M., and Lanier, L. L. (2010). Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235, 267-285.
25. Chan, C. W., Crafton, E., Fan, H. N., Flook, J., Yoshimura, K., Skarica, M., Brockstedt, D., Dubensky, T. W., Stins, M. F., Lanier, L. L., Pardoll, D. M., and Housseau, F. (2006). Interferon-producing killer dendritic cells provide a link between innate andadaptiveimmunity.Nat.Med.12, 207-213.
26. Dann, S. M., Wang, H. C., Gambarin, K. J., Actor, J. K., Robinson, P., Lewis, D. E., Caillat-Zucman, S., and White, A. C. Jr. (2005). Interleukin- 15 activates human natural killer cells to clear the intestinal protozoan cryptosporidium. J. Infect. Dis. 192, 1294-1302.
27. Dhanji, S., and Teh, H. S. (2003). IL-2-activated CD8+CD44high cells express both adaptive and innate immune system receptors and demonstrate specificity for syngeneic tumor cells. J. Immunol. 171, 3442-3450.
28. Dunn, C., Chalupny, N. J., Sutherland, C. L., Dosch, S., Sivakumar, P. V., Johnson, D. C., and Cosman, D. (2003). Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands,protectingagainstnaturalkiller cell cytotoxicity. J. Exp. Med. 197, 1427-1439.
29. Eagle, R. A., Traherne, J. A., Hair, J. R., Jafferji, I., and Trowsdale, J. (2009). ULBP6/RAET1L is an additional human NKG2D ligand. Eur. J. Immunol. 39, 3207-3216.
30. Eagle, R. A., and Trowsdale, J. (2007). Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 7, 737-744.
31. Ebert, E. C. (2005). IL-15 converts human intestinal intraepithelial lymphocytes to CD94 producers of IFN-gamma and IL-10, the latter promoting Fas ligand-mediated cytotoxicity. Immunology 115, 118-126.
32. Fernández-Messina, L. (2011). Studies on the biochemistry and cell biology of the glycosyl-phosphatidylinositol (GPI)-anchored NKG2D-ligands. PhD thesis,University of Cambridge, Cambridge.
33. Fernandez-Messina, L., Ashiru, O., Aguera-Gonzalez, S., Reyburn, H. T., and Vales-Gomez, M. (2011). The humanNKG2DligandULBP2canbe expressed at the cell surface with or withoutaGPIanchorandbothforms can activate NK cells. J. Cell Sci. 124, 321-327.
34. Fernandez-Messina, L., Ashiru, O., Boutet,P.,Aguera-Gonzalez,S.,Skepper, J. N., Reyburn, H. T., and Vales-Gomez, M. (2010). Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)- anchored NKG2D ligands. J. Biol. Chem. 285,8543-8551.
35. Gilfillan, S., Ho, E. L., Cella, M., Yokoyama, W. M., and Colonna, M. (2002). NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3, 1150-1155.
36. Gonzalez, S., Lopez-Soto, A., Suarez- Alvarez, B., Lopez-Vazquez, A., and Lopez-Larrea,C. (2008). NKG2D ligands: key targets of the immune response. Trends Immunol. 29, 397-403.
37. Groh, V., Bahram, S., Bauer, S., Herman, A., Beauchamp, M., and Spies, T. (1996). Cell stressregulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. U.S.A. 93, 12445-12450.
38. Groh, V., Bruhl, A., El-Gabalawy, H., Nelson, J. L., and Spies, T. (2003). Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 100, 9452-9457.
39. Groh, V., Rhinehart, R., Randolph- Habecker, J., Topp, M. S., Riddell, S. R., and Spies, T. (2001). Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2,255-260.
40. Groh, V., Smythe, K., Dai, Z., and Spies,T. (2006). Fas-ligand-mediated paracrine T cell regulation by the receptorNKG2Dintumorimmunity. Nat. Immunol. 7,755-762.
41. Hedlund, M., Stenqvist,A. C., Nagaeva, O., Kjellberg, L., Wulff, M., Baranov, V., and Mincheva-Nilsson, L. (2009). Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J. Immunol. 183,340-351.
42. Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., and Paschen, A. (2012). Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 72, 460-471.
43. Houchins, J. P., Yabe, T., Mcsherry, C., and Bach, F. H. (1991). DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J. Exp. Med. 173,1017-1020.
44. Hue, S., Mention, J. J., Monteiro, R. C., Zhang, S., Cellier, C., Schmitz, J., Verkarre, V., Fodil, N., Bahram, S., Cerf-Bensussan, N., and Caillat- Zucman, S. (2004). A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21,367-377.
45. Jamieson,A.M.,Diefenbach,A.,Mcmahon, C. W., Xiong, N., Carlyle, J. R., and Raulet, D. H. (2002). The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17,19-29.
46. Jinushi, M., Takehara, T., Kanto, T., Tatsumi, T., Groh, V., Spies, T., Miyagi, T., Suzuki, T., Sasaki,Y., and Hayashi, N. (2003). Critical role of MHC class I-relatedchainAandBexpressionon IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J. Immunol. 170,1249-1256.
47. Kaiser, B. K.,Yim, D., Chow, I. T., Gonzalez,S.,Dai,Z.,Mann,H.H.,Strong, R. K., Groh, V., and Spies, T. (2007). Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447, 482-486.
48. Li, K., Mandai, M., Hamanishi, J., Matsumura, N., Suzuki, A., Yagi, H., Yamaguchi, K., Baba, T., Fujii, S., and Konishi, I. (2009). Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol. Immunother. 58, 641-652.
49. Li, P., Morris, D. L., Willcox, B. E., Steinle, A., Spies, T., and Strong, R. K. (2001). Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat. Immunol. 2,443-451.
50. Lou,Z.,Jevremovic,D.,Billadeau,D.D., and Leibson, P. J. (2000). A balance between positive and negative signals in cytotoxic lymphocytes regulates the polarization of lipid rafts duringthedevelopmentof cell-mediated killing. J. Exp. Med. 191,347-354.
51. Maasho, K., Opoku-Anane, J., Marusina, A. I., Coligan, J. E., and Borrego, F. (2005). NKG2D is a costimulatory receptor for human naive CD8+ T cells. J. Immunol. 174, 4480-4484.
52. Maeda, Y., and Kinoshita, T. (2011). Structural remodeling, trafficking and functions of glycosylphos- phatidylinositol-anchored proteins. Prog. Lipid Res. 50,411-424.
53. Martinez,E.,Brzostowski,J.A.,Long,E. O., and Gross, C. C. (2011). Cutting edge: NKG2D-dependent cytotoxicity is controlled by ligand distribution in the target cell membrane. J. Immunol. 186,5538-5542.
54. McFarland,B.J.,Kortemme,T.,Yu,S.F., Baker, D., and Strong, R. K. (2003). Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure 11,411-422.
55. McGilvray, R. W., Eagle, R. A., Rolland, P., Jafferji, I., Trowsdale, J., and Durrant, L. G. (2010). ULBP2 and RAET1E NKG2D ligands are independentpredictorsof poorprognosis in ovarian cancer patients. Int. J. Cancer 127,1412-1420.
56. McGilvray, R. W., Eagle, R. A., Watson, N. F., Al-Attar, A., Ball, G., Jafferji, I., Trowsdale, J., and Durrant, L. G. (2009). NKG2D ligand expression in humancolorectalcancerrevealsassociations with prognosis and evidence forimmunoediting. Clin. CancerRes. 15, 6993-7002.
57. Meresse, B., Chen, Z., Ciszewski, C., Tretiakova, M., Bhagat, G., Krausz, T. N., Raulet, D. H., Lanier, L. L., Groh, V., Spies, T., Ebert, E. C., Green, P. H., and Jabri, B. (2004). Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21, 357-366.
58. Mistry, A. R., and O'Callaghan, C. A. (2007). Regulation of ligands for the activating receptor NKG2D. Immunology 121, 439-447.
59. Muller, S., Zocher, G., Steinle, A., and Stehle, T. (2010). Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands. PLoS Pathog. 6, e1000723. doi: 10.1371/journal.ppat.1000723
60. Muntasell, A., Magri, G., Pende, D., Angulo, A., and Lopez-Botet, M. (2010). Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood 115,5170-5179.
61. Nachmani, D., Stern-Ginossar, N., Sarid, R., and Mandelboim, O. (2009). Diverse herpesvirus microR- NAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 5, 376-385.
62. Nausch, N., and Cerwenka, A. (2008). NKG2D ligands in tumor immunity. Oncogene 27, 5944-5958.
63. Nuckel, H., Switala, M., Sellmann, L., Horn, P. A., Durig, J., Duhrsen, U., Kuppers, R., Grosse-Wilde, H., and Rebmann, V. (2010). The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 24, 1152-1159.
64. O'Callaghan, C. A., Cerwenka,A., Willcox, B. E., Lanier, L. L., and Bjorkman, P. J. (2001). Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity 15, 201-211.
65. Ohashi,M.,Eagle,R.A.,and Trowsdale, J. (2010). Post-translational modificationoftheNKG2DligandRAET1G leads to cell surface expression of a glycosylphosphatidylinositollinked isoform. J. Biol. Chem. 285, 16408-16415.
66. Oppenheim, D. E., Roberts, S. J., Clarke, S. L., Filler, R., Lewis, J. M., Tigelaar, R. E., Girardi, M., and Hayday, A. C. (2005). Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immuno- surveillance. Nat. Immunol. 6, 928-937.
67. Ota, M., Katsuyama, Y., Mizuki, N., Ando, H., Furihata, K., Ono, S., Pivetti-Pezzi, P., Tabbara, K. F., Palimeris, G. D., Nikbin, B., Davatchi, F., Chams, H., Geng, Z., Bahram, S., and Inoko, H. (1997). Trinucleotiderepeatpolymorphismwithin exon5of theMICAgene(MHCclass I chain-related gene A): allele frequency data in the nine population groups Japanese,Northern Han,Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. Tissue Antigens 49, 448-454.
68. Paschen,A., Sucker,A., Hill, B., Moll, I., Zapatka, M., Nguyen, X. D., Sim, G. C., Gutmann, I., Hassel, J., Becker, J. C., Steinle, A., Schadendorf, D., and Ugurel,S.(2009).Differentialclinical significanceofindividualNKG2Dligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin. Cancer Res. 15, 5208-5215.
69. Radaev, S., Rostro, B., Brooks, A. G., Colonna, M., and Sun, P. D. (2001). Conformationalplasticityrevealedby thecocrystalstructureofNKG2Dand its class I MHC-like ligand ULBP3. Immunity 15,1039-1049.
70. Raulet, D. H. (2003). Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3, 781-790.
71. Roda-Navarro, P., and Reyburn, H. T. (2009). The traffic of the NKG2D/Dap10 receptor complex during natural killer (NK) cell activation. J. Biol. Chem. 284, 16463- 16472.
72. Rolle, A., Mousavi-Jazi, M., Eriksson, M., Odeberg, J., Soderberg- Naucler, C., Cosman, D., Karre, K., and Cerboni, C. (2003). Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J. Immunol. 171, 902-908.
73. Sabharanjak, S., and Mayor, S. (2004). Folate receptor endocytosis and trafficking. Adv. Drug Deliv. Rev. 56, 1099-1109.
74. Saez-Borderias, A., Guma, M., Angulo, A., Bellosillo, B., Pende, D., and Lopez-Botet, M. (2006). Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.Eur.J.Immunol.36, 3198-3206
75. Salih, H. R., Holdenrieder, S., and Steinle, A. (2008). Soluble NKG2D ligands:prevalence,release,andfunctional impact. Front. Biosci. 13, 3448-3456.
76. Salih, H. R., Rammensee, H. G., and Steinle, A. (2002). Cutting edge: down-regulationof MICAonhuman tumors by proteolytic shedding. J. Immunol. 169,4098-4102.
77. Schneider, C. L., and Hudson, A. W. (2011). The human herpesvirus- 7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB. PLoS Pathog. 7, e1002362. doi: 10.1371/journal.ppat.1002362
78. Schrambach, S., Ardizzone, M., Leymarie, V., Sibilia, J., and Bahram, S. (2007). In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoSONE 2,e518.doi:10.1371/journal.pone.0000518
79. Schwinn, N., Vokhminova, D., Sucker, A., Textor, S., Striegel, S., Moll, I., Nausch, N., Tuettenberg, J., Steinle, A., Cerwenka, A., Schadendorf, D., and Paschen, A. (2009). Interferongamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int. J. Cancer 124, 1594-1604.
80. Simons, M., and Raposo, G. (2009). Exosomes - vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 21,575-581.
81. Snyder, M. R., Weyand, C. M., and Goronzy, J. J. (2004). The double life of NK receptors: stimulation or co-stimulation? Trends Immunol. 25, 25-32.
82. Steinle, A., Li, P., Morris, D. L., Groh, V., Lanier, L. L., Strong, R. K., and Spies, T. (2001). Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53, 279-287.
83. Stephens, H. A. (2001). MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol. 22,378-385.
84. Stern-Ginossar, N., Gur, C., Biton, M., Horwitz, E., Elboim, M., Stanietsky, N., Mandelboim, M., and Mandelboim, O. (2008). Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat. Immunol. 9, 1065-1073.
85. Strong, R. K., and McFarland, B. J. (2004). NKG2D and related immunoreceptors. Adv. Protein Chem. 68, 281-312.
86. Suarez-Alvarez, B., Lopez-Vazquez, A., Diaz-Molina, B., Bernardo- Rodriguez, M. J., Alvarez-Lopez, R., Pascual, D., Astudillo, A., Martinez- Borra, J., Lambert, J. L., Gonzalez, S., and Lopez-Larrea, C. (2006). The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection. Transplantation 82, 354-361.
87. Takaki, R., Hayakawa, Y., Nelson, A., Sivakumar, P. V., Hughes, S., Smyth, M. J., and Lanier, L. L. (2005). IL- 21enhancestumorrejectionthrough a NKG2D-dependent mechanism. J. Immunol. 175,2167-2173.
88. Thomas, M., Boname, J. M., Field, S., Nejentsev, S., Salio, M., Cerundolo, V., Wills, M., and Lehner, P. J. (2008). Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 105, 1656-1661.
89. Upshaw, J. L., Arneson, L. N., Schoon, R. A., Dick, C. J., Billadeau, D. D., and Leibson, P. J. (2006). NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3- kinase in human natural killer cells. Nat. Immunol. 7,524-532.
90. Vales-Gomez, M., Browne, H., and Reyburn, H. T. (2003). Expression of the UL16 glycoprotein of human cytomegalovirus protects the virus- infected cell from attack by natural killer cells. BMC Immunol. 4, 4. doi: 10.1186/1471-2172-4-4
91. Vales-Gomez, M., Chisholm, S. E., Cassady-Cain, R. L., Roda-Navarro, P., and Reyburn, H. T. (2008). Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 68,1546-1554.
92. Vales-Gomez, M., Winterhalter, A., Roda-Navarro, P., Zimmermann, A., Boyle, L., Hengel, H., Brooks,A., and Reyburn, H. T. (2006). The human cytomegalovirus glycoprotein UL16 traffics through the plasma membrane and the nuclear envelope. Cell. Microbiol. 8,581-590.
93. Van Belle, T. L., and von Herrath, M. G. (2009). The role of the activating receptor NKG2D in autoimmunity. Mol. Immunol. 47,8-11.
94. Verneris, M. R., Karami, M., Baker, J., Jayaswal, A., and Negrin, R. S. (2004). Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103, 3065-3072.
95. Viaud,S.,Terme,M.,Flament,C.,Taieb, J., Andre, F., Novault, S., Escudier, B., Robert, C., Caillat-Zucman, S., Tursz, T., Zitvogel, L., and Chaput,N.(2009).Dendriticcell-derived exosomes promote natural killer cell activationandproliferation:arolefor NKG2D ligands and IL-15Rα. PLoS ONE 4, e4942. doi: 10.1371/journal.pone.0004942
96. Waldhauer, I., and Steinle, A. (2006). Proteolytic release of soluble UL16- binding protein 2 from tumor cells. Cancer Res. 66,2520-2526.
97. Welte, S. A., Sinzger, C., Lutz, S. Z., Singh-Jasuja, H., Sampaio, K. L., Eknigk, U., Rammensee, H. G., and Steinle, A. (2003). Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur. J. Immunol. 33, 194-203.
98. Wiemann, K., Mittrucker, H. W., Feger, U., Welte, S. A., Yokoyama, W. M., Spies, T., Rammensee, H. G., and Steinle, A. (2005). Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175,720-729.
99. Wolan, D. W., Teyton, L., Rudolph, M. G., Villmow, B., Bauer, S., Busch, D. H., and Wilson, I. A. (2001). Crystal structure of the murine NK cell- activatingreceptorNKG2Dat1.95A. Nat. Immunol. 2,248-254.
100. Wu, J., Song, Y., Bakker, A. B., Bauer, S., Spies, T., Lanier, L. L., and Phillips, J. H. (1999). An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285, 730-732.
101. Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K., and Plymate, S. R. (2004). Prevalent expression of the immunostimulatory MHC class I chain-related moleculeiscounteractedbyshedding in prostate cancer. J. Clin. Invest. 114, 560-568.
102. Yadav, D., Ngolab, J., Lim, R. S., Krishnamurthy, S., and Bui, J. D. (2009). Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma- induced microRNA. J. Immunol. 182, 39-43.
103. Zhang, C., Niu, J., Zhang, J., Wang, Y., Zhou, Z., and Tian, Z. (2008). Opposing effects of interferon- alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. Cancer Sci. 99, 1279-1286.